Dyslipidaemia
Clinical trials for Dyslipidaemia explained in plain language.
Never miss a new study
Get alerted when new Dyslipidaemia trials appear
Sign up with your email to follow new studies for Dyslipidaemia, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New pill combo aims to crush bad cholesterol
Disease control OngoingThis study tests whether adding a new drug called AZD0780 to the common statin rosuvastatin can lower 'bad' LDL cholesterol more than rosuvastatin alone. About 76 adults with high cholesterol will take either AZD0780 or a placebo pill, plus rosuvastatin, for 12 weeks. Neither par…
Matched conditions: DYSLIPIDAEMIA
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New pill could help control high cholesterol – study underway
Disease control OngoingThis study tests an experimental oral drug called AZD0780 in 432 adults with high LDL cholesterol (dyslipidaemia). Participants take the drug or a placebo daily for up to 52 weeks to see if it safely lowers cholesterol. The goal is to manage the condition, not cure it, as ongoing…
Matched conditions: DYSLIPIDAEMIA
Phase 2/3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Could a diabetes drug turn back the biological clock in HIV?
Disease control By invitation onlyThis study investigates whether tirzepatide, a drug used for diabetes and weight loss, can reverse biological aging in people with HIV who are virally suppressed and have obesity. Participants receive tirzepatide for 25 weeks after a diet program. Researchers measure epigenetic a…
Matched conditions: DYSLIPIDAEMIA
Phase 4 • Sponsor: National Taiwan University Clinical Trial Center • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Diet or drugs? new study tests if fasting beats pills for fatty liver disease
Disease control By invitation onlyThis study tests whether a Mediterranean diet combined with intermittent fasting can reduce liver scarring (fibrosis) better than the weight-loss medication naltrexone/bupropion. About 70 adults with overweight or obesity and heart or metabolic risks (like type 2 diabetes or high…
Matched conditions: DYSLIPIDAEMIA
Phase 4 • Sponsor: Carmen Dietvorst • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC